SGLT2i, Pioglitazone, and Ketone Production in T2D — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

SGLT2i, Pioglitazone, and Ketone Production in T2D — Stella

Home/Type 2 Diabetes/

View on ClinicalTrials.gov

Recruiting

Back to Type 2 Diabetes trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Texas Diabetes Institute/UH, San Antonio, Texas

Key details

Phase

Early testing

Sponsor

The University of Texas Health Science Center at San Antonio

Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Enrollment target

~64 participants

Started

July 2026

Primary completion

June 2027

Age range

30 Years – 75 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.